""lˈæɹətɹˌɛktɪnˌɪb"" ɪz ɐn ɪnhˈɪbɪɾɚ tʊ ˈɔːl ʌvðə tˌiːˌɑːɹkˈeɪ ɹᵻsˈɛptɚz tˌiːˌɑːɹkˈeɪ ˈeɪ, tˌiːˌɑːɹkˈeɪ bˈiː, ænd tˌiːˌɑːɹkˈeɪ sˈiː ænd ðə dɹˈʌɡ ɪz jˈuːzd æz ɐ tɹˈiːtmənt fɔːɹ tˈuːmɚz wɪð tˌiːˌɑːɹkˈeɪ fjˈuːʒənz.
""Larotrectinib"" is an inhibitor to all of the Trk receptors (TrkA, TrkB, and TrkC) and the drug is used as a treatment for tumors with Trk fusions.